Zenas BioPharma, Inc. cash flow to debt ratio of -215.52% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Zenas BioPharma, Inc.'s free cash flow has decreased 43.86% from $-119.81M last year to $-172.35M, signaling decreasing performance

Zenas BioPharma, Inc.'s debt to equity ratio is 1.05, which means that the company's assets are unhealthy financed, signaling financial risk.

Zenas BioPharma, Inc.'s debt has increased relative to shareholder equity from 0.00 last year to 1.05 today, signaling weakened financials

Zenas BioPharma, Inc. has a net cash position, so leverage is healthy.

Zenas BioPharma, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Zenas BioPharma, Inc.'s profit margin has increased (-100.00%) in the last year from -3.14K% to 0.00%, signaling increasing performance

Zenas BioPharma, Inc.'s short-term assets of $351.17M exceed its short-term liabilities of $62.65M

Zenas BioPharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Zenas BioPharma, Inc.'s return on equity of -167.71%, is lower than 15.00%, indicating bad performance

Zenas BioPharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Zenas BioPharma, Inc. has insufficient public price history to evaluate earnings stability.

Zenas BioPharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Zenas BioPharma, Inc. has negative free cash flow, indicating cash burn

Zenas BioPharma, Inc.'s yearly earnings has decreased 140.62% since last year from $-156.99M to $-377.74M, signaling decreasing performance

Zenas BioPharma, Inc.'s yearly revenue has increased 100.00% since last year from $5.00M to $10.00M, signaling increasing performance

ROIC -61.53% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Zenas BioPharma, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Zenas BioPharma, Inc. has insufficient public price history to evaluate revenue consistency.

Zenas BioPharma, Inc. has insufficient public price history to evaluate ROE consistency.

Zenas BioPharma, Inc. has insufficient data to evaluate this check.

Zenas BioPharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Zenas BioPharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Zenas BioPharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Zenas BioPharma, Inc. has insufficient data to evaluate this check.

Zenas BioPharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Zenas BioPharma, Inc. has a price-to-book ratio of 5.30x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Zenas BioPharma, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue